// =============================================================================
// Companion Diagnostic (CDx) Competitor Database
// =============================================================================
// 55+ CDx/molecular diagnostic tests organized by biomarker and platform.
// Used by the CDx competitive landscape engine.
//
// Sources: FDA PMA database, CMS MolDx coverage decisions, company 10-K filings,
// Evaluate MedTech, GenomeWeb, 2024-2025 data.
// =============================================================================

import type { CDxCompetitor, CDxPlatform } from '@/types/devices-diagnostics';

// =============================================================================
// COMPREHENSIVE NGS PANELS
// =============================================================================

const NGS_PANELS: CDxCompetitor[] = [
  {
    company: 'Foundation Medicine',
    test_name: 'FoundationOne CDx',
    platform: 'NGS',
    biomarkers_covered: [
      'EGFR',
      'ALK',
      'ROS1',
      'BRAF',
      'KRAS',
      'NTRK',
      'HER2',
      'MET',
      'RET',
      'PIK3CA',
      'BRCA1',
      'BRCA2',
      'TMB',
      'MSI',
    ],
    linked_drugs: [
      'Keytruda (pembrolizumab)',
      'Lynparza (olaparib)',
      'Rozlytrek (entrectinib)',
      'Vitrakvi (larotrectinib)',
      'Tagrisso (osimertinib)',
      'Lumakras (sotorasib)',
      'Enhertu (T-DXd)',
      'Tabrecta (capmatinib)',
    ],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 324,
    turnaround_days: 14,
    test_price_estimate: 5800,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 250000,
    estimated_revenue_m: 1200,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Broadest FDA-approved CDx panel',
      'Most drug label linkages (>30)',
      'NCD 90.2 coverage',
      'Gold standard for tissue CGP',
    ],
    weaknesses: [
      'Tissue-only (no liquid)',
      'Slow turnaround vs PCR',
      'Requires adequate tissue sample',
      'High per-test cost',
    ],
    source: 'Roche 10-K 2024; FDA PMA P170019',
    last_updated: '2025-01',
  },
  {
    company: 'Foundation Medicine',
    test_name: 'FoundationOne Liquid CDx',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'BRCA1', 'BRCA2', 'MET', 'RET', 'PIK3CA', 'ERBB2'],
    linked_drugs: ['Tagrisso (osimertinib)', 'Lynparza (olaparib)', 'Rybrevant (amivantamab)', 'Rubraca (rucaparib)'],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 324,
    turnaround_days: 10,
    test_price_estimate: 5800,
    sample_type: ['blood'],
    estimated_annual_test_volume: 80000,
    estimated_revenue_m: 400,
    differentiation_score: 8,
    evidence_strength: 9,
    strengths: [
      'FDA-approved liquid biopsy CGP',
      'Blood draw (no biopsy needed)',
      'Monitors treatment response',
      'Broad panel',
    ],
    weaknesses: [
      'Lower sensitivity than tissue for some variants',
      'Higher false-negative rate for CNS-only disease',
      'Expensive',
    ],
    source: 'Roche 10-K 2024; FDA PMA P200006',
    last_updated: '2025-01',
  },
  {
    company: 'Tempus',
    test_name: 'Tempus xT',
    platform: 'NGS',
    biomarkers_covered: [
      'EGFR',
      'ALK',
      'ROS1',
      'BRAF',
      'KRAS',
      'NTRK',
      'HER2',
      'MET',
      'RET',
      'PIK3CA',
      'BRCA1',
      'BRCA2',
      'TMB',
      'MSI',
      'PD-L1',
    ],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 648,
    turnaround_days: 14,
    test_price_estimate: 5200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 180000,
    estimated_revenue_m: 700,
    differentiation_score: 8,
    evidence_strength: 7,
    strengths: [
      'Largest gene panel (648 genes)',
      'AI-powered variant interpretation',
      'Integrated clinical-genomic database',
      'Fast-growing market share',
    ],
    weaknesses: [
      'LDT — not FDA approved',
      'Payer coverage inconsistent',
      'No CDx drug linkages',
      'Newer entrant vs F1',
    ],
    source: 'Tempus S-1 filing 2024; GenomeWeb',
    last_updated: '2025-01',
  },
  {
    company: 'Tempus',
    test_name: 'Tempus xF',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['EGFR', 'ALK', 'BRAF', 'KRAS', 'MET', 'RET', 'ERBB2', 'PIK3CA', 'BRCA1', 'BRCA2'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 105,
    turnaround_days: 7,
    test_price_estimate: 3800,
    sample_type: ['blood'],
    estimated_annual_test_volume: 60000,
    estimated_revenue_m: 180,
    differentiation_score: 7,
    evidence_strength: 6,
    strengths: [
      'Faster turnaround than F1 Liquid',
      'Lower cost',
      'Integrated with Tempus OS',
      'Growing oncology network',
    ],
    weaknesses: ['LDT status', 'Smaller panel than F1 Liquid', 'No FDA-approved CDx claims', 'Limited payer coverage'],
    source: 'Tempus S-1 filing 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Caris Life Sciences',
    test_name: 'Caris Molecular Intelligence (MI)',
    platform: 'NGS',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'NTRK', 'HER2', 'MET', 'RET', 'TMB', 'MSI', 'PD-L1'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 592,
    turnaround_days: 14,
    test_price_estimate: 5400,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 120000,
    estimated_revenue_m: 500,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'Whole exome + transcriptome',
      'Multi-omic profiling (DNA + RNA + protein)',
      'Strong lab network',
      '30K+ oncologists in network',
    ],
    weaknesses: ['LDT status', 'Less brand recognition than F1', 'No CDx approvals', 'Complex multi-omic reports'],
    source: 'GenomeWeb; Caris press releases 2024',
    last_updated: '2025-01',
  },
  {
    company: 'NeoGenomics',
    test_name: 'NeoTYPE Discovery Profile',
    platform: 'NGS',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'MET', 'RET', 'NTRK', 'TMB', 'MSI'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 340,
    turnaround_days: 12,
    test_price_estimate: 4800,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 50000,
    estimated_revenue_m: 180,
    differentiation_score: 6,
    evidence_strength: 6,
    strengths: [
      'Integrated lab services company',
      'Fast turnaround',
      'Strong pathology expertise',
      'Regional lab footprint',
    ],
    weaknesses: [
      'Smaller scale than F1/Tempus',
      'LDT only',
      'Limited liquid biopsy offerings',
      'Revenue under pressure',
    ],
    source: 'NeoGenomics 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Thermo Fisher Scientific',
    test_name: 'Oncomine Dx Target Test',
    platform: 'NGS',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'MET', 'RET', 'HER2', 'NTRK'],
    linked_drugs: ['Tagrisso (osimertinib)', 'Xalkori (crizotinib)', 'Rozlytrek (entrectinib)'],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 23,
    turnaround_days: 4,
    test_price_estimate: 2800,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 40000,
    estimated_revenue_m: 90,
    differentiation_score: 6,
    evidence_strength: 8,
    strengths: [
      'FDA PMA approved',
      'Very fast turnaround',
      'Runs on Ion Torrent platform (broadly installed)',
      'Lower cost per test',
    ],
    weaknesses: ['Small panel (23 genes)', 'Limited to NSCLC', 'Being overtaken by larger panels', 'No liquid biopsy'],
    source: 'FDA PMA P160045; Thermo Fisher 10-K 2024',
    last_updated: '2025-01',
  },
];

// =============================================================================
// LIQUID BIOPSY SPECIALISTS
// =============================================================================

const LIQUID_BIOPSY: CDxCompetitor[] = [
  {
    company: 'Guardant Health',
    test_name: 'Guardant360 CDx',
    platform: 'liquid_biopsy',
    biomarkers_covered: [
      'EGFR',
      'ALK',
      'ROS1',
      'BRAF',
      'KRAS',
      'NTRK',
      'HER2',
      'MET',
      'RET',
      'PIK3CA',
      'BRCA1',
      'BRCA2',
      'TMB',
      'MSI',
    ],
    linked_drugs: ['Tagrisso (osimertinib)', 'Rybrevant (amivantamab)', 'Lumakras (sotorasib)'],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 74,
    turnaround_days: 7,
    test_price_estimate: 5000,
    sample_type: ['blood'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 800,
    differentiation_score: 9,
    evidence_strength: 9,
    strengths: [
      'Market-leading liquid biopsy',
      'Fastest turnaround (7 days)',
      'FDA CDx approvals',
      '300K+ tests/year',
      'Real-world data platform',
    ],
    weaknesses: [
      'Blood-only (miss tissue-only variants)',
      'Smaller panel vs tissue NGS',
      'Profitability challenges',
      'Competition from F1 Liquid',
    ],
    source: 'Guardant Health 10-K 2024; FDA PMA P200010',
    last_updated: '2025-01',
  },
  {
    company: 'Guardant Health',
    test_name: 'Guardant360 TissueNext',
    platform: 'NGS',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'NTRK', 'MET', 'RET', 'HER2', 'TMB', 'MSI'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 500,
    turnaround_days: 10,
    test_price_estimate: 5200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 30000,
    estimated_revenue_m: 120,
    differentiation_score: 6,
    evidence_strength: 6,
    strengths: ['Complements liquid biopsy', 'Whole exome option', 'Growing tissue business'],
    weaknesses: ['Newer offering', 'LDT only', 'Competes against established tissue players', 'Small volume vs F1'],
    source: 'Guardant Health 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Guardant Health',
    test_name: 'GuardantReveal',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['ctDNA (MRD)', 'MSI'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 74,
    turnaround_days: 7,
    test_price_estimate: 3500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 25000,
    estimated_revenue_m: 70,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'MRD detection for CRC',
      'Serial monitoring capability',
      'Growing evidence base',
      'NCCN guideline included',
    ],
    weaknesses: ['LDT status', 'Competes with Signatera', 'Limited to CRC initially', 'Reimbursement uncertain'],
    source: 'Guardant Health 10-K 2024; ECLIPSE trial',
    last_updated: '2025-01',
  },
  {
    company: 'Guardant Health',
    test_name: 'Shield',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['cfDNA methylation (CRC screening)'],
    linked_drugs: [],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 0,
    turnaround_days: 10,
    test_price_estimate: 895,
    sample_type: ['blood'],
    estimated_annual_test_volume: 50000,
    estimated_revenue_m: 40,
    differentiation_score: 8,
    evidence_strength: 8,
    strengths: [
      'First blood-based CRC screening test',
      'FDA approved 2024',
      'CMS coverage pathway',
      'Massive TAM (50M+ eligible adults)',
    ],
    weaknesses: [
      'Lower sensitivity vs Cologuard (83% vs 93%)',
      'Lower specificity',
      'Reimbursement rate uncertain',
      'Consumer awareness low',
    ],
    source: 'FDA PMA P230014; Guardant ECLIPSE trial',
    last_updated: '2025-01',
  },
  {
    company: 'Biodesix',
    test_name: 'GeneStrat ddPCR',
    platform: 'ddPCR',
    biomarkers_covered: ['EGFR', 'KRAS', 'BRAF', 'ALK', 'ROS1', 'MET', 'RET'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 7,
    turnaround_days: 3,
    test_price_estimate: 1800,
    sample_type: ['blood'],
    estimated_annual_test_volume: 30000,
    estimated_revenue_m: 45,
    differentiation_score: 6,
    evidence_strength: 6,
    strengths: [
      'Fastest liquid biopsy turnaround (3 days)',
      'Low cost per test',
      'Combined with VeriStrat protein test',
      'Lung-focused',
    ],
    weaknesses: ['Narrow panel', 'ddPCR platform less scalable', 'Small market share', 'Not FDA-approved CDx'],
    source: 'Biodesix 10-K 2024',
    last_updated: '2025-01',
  },
];

// =============================================================================
// SCREENING & EARLY DETECTION
// =============================================================================

const SCREENING: CDxCompetitor[] = [
  {
    company: 'Exact Sciences',
    test_name: 'Cologuard Plus',
    platform: 'PCR',
    biomarkers_covered: ['KRAS', 'NDRG4', 'BMP3', 'hemoglobin', 'methylation markers'],
    linked_drugs: [],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 5,
    turnaround_days: 10,
    test_price_estimate: 649,
    sample_type: ['stool'],
    estimated_annual_test_volume: 4500000,
    estimated_revenue_m: 2200,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Dominant CRC screening test',
      '4.5M+ tests/year',
      'At-home collection',
      'CMS coverage at $649',
      'BLUE-C trial data',
    ],
    weaknesses: [
      'Stool-based (compliance barrier)',
      '3-year interval',
      'False positive rate ~13%',
      'Competition from blood-based tests',
    ],
    source: 'Exact Sciences 10-K 2024; FDA PMA P130017',
    last_updated: '2025-01',
  },
  {
    company: 'GRAIL (Illumina)',
    test_name: 'Galleri',
    platform: 'NGS',
    biomarkers_covered: ['cfDNA methylation (50+ cancer types)'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 0,
    turnaround_days: 14,
    test_price_estimate: 949,
    sample_type: ['blood'],
    estimated_annual_test_volume: 150000,
    estimated_revenue_m: 120,
    differentiation_score: 10,
    evidence_strength: 7,
    strengths: [
      'Multi-cancer early detection (50+ types)',
      'Blood-based',
      'First-mover in MCED',
      'NHS pilot study (140K participants)',
      'Cancer Signal Origin localization',
    ],
    weaknesses: [
      'No FDA approval yet',
      'Self-pay only',
      'Low sensitivity for Stage I',
      'High cost',
      'Illumina divestiture uncertainty',
    ],
    source: 'GRAIL press releases; PATHFINDER trial; GenomeWeb',
    last_updated: '2025-01',
  },
  {
    company: 'Freenome',
    test_name: 'Freenome CRC Blood Test',
    platform: 'NGS',
    biomarkers_covered: ['cfDNA methylation', 'protein biomarkers (CRC)'],
    linked_drugs: [],
    regulatory_status: 'development',
    genes_in_panel: 0,
    turnaround_days: 10,
    test_price_estimate: 800,
    sample_type: ['blood'],
    estimated_annual_test_volume: 0,
    estimated_revenue_m: 0,
    differentiation_score: 7,
    evidence_strength: 5,
    strengths: [
      'Multi-omic approach (cfDNA + protein)',
      'PREEMPT pivotal trial ongoing',
      'Roche partnership',
      'Strong funding ($1B+)',
    ],
    weaknesses: ['Pre-market', 'Crowded CRC screening space', 'No FDA submission yet', 'Late vs Guardant Shield'],
    source: 'Freenome press releases; PREEMPT trial NCT04369053',
    last_updated: '2025-01',
  },
];

// =============================================================================
// MRD / RECURRENCE MONITORING
// =============================================================================

const MRD_MONITORING: CDxCompetitor[] = [
  {
    company: 'Natera',
    test_name: 'Signatera',
    platform: 'PCR',
    biomarkers_covered: ['ctDNA (personalized MRD)', 'tumor-informed SNVs'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 16,
    turnaround_days: 10,
    test_price_estimate: 3500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 550,
    differentiation_score: 9,
    evidence_strength: 9,
    strengths: [
      'Market leader in MRD',
      'Tumor-informed (custom per patient)',
      'Serial monitoring',
      'CMS coverage (CRC, breast, bladder)',
      'NCCN guideline included',
    ],
    weaknesses: [
      'Requires tumor tissue for panel design',
      'Longer initial turnaround',
      'Expensive per patient lifecycle',
      'PCR-based (limited sensitivity floor)',
    ],
    source: 'Natera 10-K 2024; CIRCULATE-Japan; IMvigor010',
    last_updated: '2025-01',
  },
  {
    company: 'Invivoscribe',
    test_name: 'ClonoSEQ',
    platform: 'NGS',
    biomarkers_covered: ['IgH VDJ', 'IgH DJ', 'IgK', 'TCRβ', 'TCRδ', 'TCRγ (MRD hematologic)'],
    linked_drugs: [],
    regulatory_status: 'cleared',
    genes_in_panel: 6,
    turnaround_days: 5,
    test_price_estimate: 3100,
    sample_type: ['blood', 'bone marrow'],
    estimated_annual_test_volume: 80000,
    estimated_revenue_m: 200,
    differentiation_score: 8,
    evidence_strength: 9,
    strengths: [
      'Only FDA-cleared MRD test',
      'Gold standard for heme MRD',
      'CMS coverage',
      'Used in major clinical trials',
      'Fast turnaround',
    ],
    weaknesses: [
      'Hematologic malignancies only',
      'Requires baseline sample',
      'Adaptive Biotechnologies financial challenges',
      'Narrow indication scope',
    ],
    source: 'FDA 510(k) K173362; Adaptive Biotechnologies 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Personalis',
    test_name: 'NeXT Personal',
    platform: 'NGS',
    biomarkers_covered: ['ctDNA (whole-genome MRD)', 'germline + somatic variants'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 20000,
    turnaround_days: 14,
    test_price_estimate: 4500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 15000,
    estimated_revenue_m: 50,
    differentiation_score: 7,
    evidence_strength: 6,
    strengths: [
      'Whole-genome approach (broadest)',
      'Detects novel fusions',
      'Pharma partnerships',
      'Growing MRD evidence',
    ],
    weaknesses: ['LDT only', 'Small commercial scale', 'Higher cost than Signatera', 'Slower turnaround'],
    source: 'Personalis 10-K 2024',
    last_updated: '2025-01',
  },
];

// =============================================================================
// IHC / PROTEIN-BASED CDx
// =============================================================================

const IHC_TESTS: CDxCompetitor[] = [
  {
    company: 'Agilent (Dako)',
    test_name: 'PD-L1 IHC 22C3 pharmDx',
    platform: 'IHC',
    biomarkers_covered: ['PD-L1 (TPS & CPS)'],
    linked_drugs: ['Keytruda (pembrolizumab)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 350,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 1500000,
    estimated_revenue_m: 450,
    differentiation_score: 8,
    evidence_strength: 10,
    strengths: [
      'Gold standard PD-L1 CDx',
      'Linked to #1 IO drug (Keytruda)',
      'Highest test volume globally',
      'CMS covered',
    ],
    weaknesses: [
      'Single biomarker only',
      'Scoring variability between pathologists',
      'Being supplemented by NGS',
      'Tissue-dependent',
    ],
    source: 'FDA PMA P150013; Agilent 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Roche (Ventana)',
    test_name: 'VENTANA PD-L1 (SP142)',
    platform: 'IHC',
    biomarkers_covered: ['PD-L1 (IC score)'],
    linked_drugs: ['Tecentriq (atezolizumab)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 340,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 500000,
    estimated_revenue_m: 140,
    differentiation_score: 7,
    evidence_strength: 9,
    strengths: [
      'Linked to Tecentriq',
      'Immune cell scoring (different algorithm)',
      'Strong Roche distribution',
      'VENTANA platform widely installed',
    ],
    weaknesses: [
      'Less dominant than 22C3',
      'Tecentriq facing competition',
      'IC scoring less familiar to pathologists',
      'Narrow drug linkage',
    ],
    source: 'FDA PMA P160002; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Roche (Ventana)',
    test_name: 'VENTANA PD-L1 (SP263)',
    platform: 'IHC',
    biomarkers_covered: ['PD-L1 (TC score)'],
    linked_drugs: ['Imfinzi (durvalumab)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 340,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 300000,
    estimated_revenue_m: 85,
    differentiation_score: 6,
    evidence_strength: 8,
    strengths: ['Linked to Imfinzi', 'EC/CE-IVD marked', 'Used in PACIFIC trial (chemoradiation + IO)'],
    weaknesses: ['Third in PD-L1 volume behind 22C3', 'Imfinzi market share declining', 'Tissue-only'],
    source: 'FDA PMA; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Agilent (Dako)',
    test_name: 'HER2 IQFISH pharmDx',
    platform: 'FISH',
    biomarkers_covered: ['HER2 amplification'],
    linked_drugs: ['Herceptin (trastuzumab)', 'Enhertu (T-DXd)', 'Kadcyla (T-DM1)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 3,
    test_price_estimate: 400,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 600000,
    estimated_revenue_m: 200,
    differentiation_score: 7,
    evidence_strength: 10,
    strengths: [
      'Gold standard HER2 FISH',
      'Linked to major HER2 drugs',
      'Long track record',
      'Confirmatory test for IHC 2+',
    ],
    weaknesses: [
      'Being replaced by IHC in many settings',
      'Labor-intensive manual scoring',
      'NGS eating into reflex testing',
    ],
    source: 'FDA PMA; Agilent 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Roche (Ventana)',
    test_name: 'VENTANA HER2 (4B5)',
    platform: 'IHC',
    biomarkers_covered: ['HER2 protein expression'],
    linked_drugs: ['Enhertu (T-DXd)', 'Herceptin (trastuzumab)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 1,
    test_price_estimate: 250,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 1200000,
    estimated_revenue_m: 250,
    differentiation_score: 7,
    evidence_strength: 10,
    strengths: [
      'Highest-volume HER2 IHC test',
      'Fastest turnaround',
      'Low-cost screening',
      'Enhertu HER2-low paradigm expanding TAM',
    ],
    weaknesses: [
      'Subjective scoring (0/1+/2+/3+)',
      'HER2-low interpretation challenges',
      'Needs FISH confirmation for 2+',
    ],
    source: 'FDA PMA; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Leica Biosystems',
    test_name: 'BOND Oracle HER2 IHC',
    platform: 'IHC',
    biomarkers_covered: ['HER2 protein expression'],
    linked_drugs: ['Herceptin (trastuzumab)'],
    regulatory_status: 'cleared',
    turnaround_days: 1,
    test_price_estimate: 220,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 35,
    differentiation_score: 5,
    evidence_strength: 7,
    strengths: ['Low cost', 'BOND platform automation', 'Fast results'],
    weaknesses: [
      'Smaller market share',
      'Less pathologist familiarity',
      'Fewer drug linkages',
      'Second tier to Ventana/Dako',
    ],
    source: 'Leica Biosystems/Danaher; FDA 510(k) database',
    last_updated: '2025-01',
  },
];

// =============================================================================
// PCR-BASED CDx
// =============================================================================

const PCR_TESTS: CDxCompetitor[] = [
  {
    company: 'Qiagen',
    test_name: 'therascreen EGFR RGQ PCR Kit',
    platform: 'PCR',
    biomarkers_covered: ['EGFR (exon 19 del, L858R, T790M, exon 20 ins)'],
    linked_drugs: ['Iressa (gefitinib)', 'Tagrisso (osimertinib)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 500,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 300000,
    estimated_revenue_m: 120,
    differentiation_score: 6,
    evidence_strength: 9,
    strengths: [
      'Fast turnaround (same day possible)',
      'Low cost per test',
      'FDA CDx approved',
      'Widely installed QIAGEN platform',
    ],
    weaknesses: [
      'Single gene only',
      'Being replaced by NGS panels',
      'Declining volume',
      'Cannot detect novel EGFR variants',
    ],
    source: 'FDA PMA P120022; QIAGEN 20-F 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Qiagen',
    test_name: 'therascreen PIK3CA RGQ PCR Kit',
    platform: 'PCR',
    biomarkers_covered: ['PIK3CA (11 mutations)'],
    linked_drugs: ['Piqray (alpelisib)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 500,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 80000,
    estimated_revenue_m: 30,
    differentiation_score: 5,
    evidence_strength: 8,
    strengths: ['FDA CDx for alpelisib', 'Fast and cheap', 'Clear-cut single biomarker result'],
    weaknesses: ['Narrow — PIK3CA only', 'Piqray commercial challenges', 'Replaced by NGS in many practices'],
    source: 'FDA PMA P190004; QIAGEN 20-F 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Roche',
    test_name: 'cobas EGFR Mutation Test v2',
    platform: 'PCR',
    biomarkers_covered: ['EGFR (42 mutations including T790M)'],
    linked_drugs: ['Tarceva (erlotinib)', 'Tagrisso (osimertinib)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 500,
    sample_type: ['tissue', 'blood'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 80,
    differentiation_score: 6,
    evidence_strength: 9,
    strengths: [
      'Tissue AND blood (plasma) sample types',
      'FDA CDx approved',
      'T790M detection from blood',
      'cobas platform widely installed',
    ],
    weaknesses: ['Single gene', 'Being replaced by NGS', 'Volume declining', 'Limited EGFR variant coverage vs NGS'],
    source: 'FDA PMA P150047; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Roche',
    test_name: 'cobas BRAF V600 Mutation Test',
    platform: 'PCR',
    biomarkers_covered: ['BRAF V600E', 'BRAF V600K'],
    linked_drugs: ['Zelboraf (vemurafenib)', 'Tafinlar+Mekinist (dabrafenib+trametinib)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 2,
    test_price_estimate: 450,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 150000,
    estimated_revenue_m: 55,
    differentiation_score: 5,
    evidence_strength: 9,
    strengths: [
      'FDA CDx approved',
      'Fast turnaround',
      'Melanoma standard of care',
      'BRAF V600 is actionable across tumor types',
    ],
    weaknesses: ['Only V600E/K (misses V600D, non-V600)', 'Being subsumed by NGS panels', 'Volume declining'],
    source: 'FDA PMA P110020; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Abbott',
    test_name: 'Vysis ALK Break Apart FISH',
    platform: 'FISH',
    biomarkers_covered: ['ALK rearrangement'],
    linked_drugs: ['Xalkori (crizotinib)', 'Alecensa (alectinib)', 'Lorbrena (lorlatinib)'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 3,
    test_price_estimate: 500,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 100000,
    estimated_revenue_m: 40,
    differentiation_score: 5,
    evidence_strength: 10,
    strengths: [
      'Original ALK CDx (gold standard historically)',
      'FDA approved',
      'Well-established protocol',
      'NCCN Category 1',
    ],
    weaknesses: ['Expensive manual scoring', 'Being replaced by IHC + NGS', 'Labor-intensive', 'Declining volume'],
    source: 'FDA PMA P110012; Abbott 10-K 2024',
    last_updated: '2025-01',
  },
];

// =============================================================================
// HEREDITARY / GERMLINE TESTING
// =============================================================================

const HEREDITARY: CDxCompetitor[] = [
  {
    company: 'Myriad Genetics',
    test_name: 'BRACAnalysis CDx',
    platform: 'PCR',
    biomarkers_covered: ['BRCA1', 'BRCA2 (germline)'],
    linked_drugs: ['Lynparza (olaparib)', 'Rubraca (rucaparib)', 'Talazoparib'],
    regulatory_status: 'PMA_approved',
    turnaround_days: 14,
    test_price_estimate: 4000,
    sample_type: ['blood'],
    estimated_annual_test_volume: 250000,
    estimated_revenue_m: 350,
    differentiation_score: 8,
    evidence_strength: 10,
    strengths: [
      'Gold standard BRCA CDx',
      'Multiple PARP inhibitor CDx linkages',
      'CMS coverage',
      '20+ year BRCA data history',
      'Direct consumer awareness',
    ],
    weaknesses: [
      'Single gene family (BRCA)',
      'Germline-only (misses somatic)',
      'Being supplemented by broader panels',
      'Myriad financial restructuring',
    ],
    source: 'FDA PMA P140020; Myriad 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Myriad Genetics',
    test_name: 'myChoice CDx',
    platform: 'NGS',
    biomarkers_covered: ['HRD (homologous recombination deficiency)', 'BRCA1', 'BRCA2', 'genomic instability score'],
    linked_drugs: ['Lynparza (olaparib)', 'Zejula (niraparib)'],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 2,
    turnaround_days: 14,
    test_price_estimate: 4200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 150000,
    estimated_revenue_m: 500,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Only FDA-approved HRD test',
      'CDx for two PARP inhibitors',
      'Genomic instability scoring (beyond BRCA)',
      'Critical for ovarian cancer treatment',
    ],
    weaknesses: [
      'Tissue required',
      'Long turnaround',
      'HRD scoring cutoff debate',
      'Competition from other HRD assays',
    ],
    source: 'FDA PMA P190014; Myriad 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Myriad Genetics',
    test_name: 'GeneSight',
    platform: 'PCR',
    biomarkers_covered: ['CYP2D6', 'CYP2C19', 'CYP2B6', 'SLC6A4', 'HTR2A', 'pharmacogenomic panel'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 12,
    turnaround_days: 5,
    test_price_estimate: 330,
    sample_type: ['buccal swab'],
    estimated_annual_test_volume: 500000,
    estimated_revenue_m: 150,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'Market leader in psychotropic pharmacogenomics',
      'GUIDED RCT data',
      'Easy buccal swab collection',
      'High patient demand',
    ],
    weaknesses: [
      'Not FDA-approved (LDT)',
      'Payer pushback on coverage',
      'Clinical utility debate',
      'Psychiatry KOL skepticism',
    ],
    source: 'Myriad 10-K 2024; GUIDED trial',
    last_updated: '2025-01',
  },
  {
    company: 'Ambry Genetics (Konica Minolta)',
    test_name: 'AmbryScore + CustomNext',
    platform: 'NGS',
    biomarkers_covered: ['BRCA1', 'BRCA2', 'PALB2', 'ATM', 'CHEK2', 'TP53', 'multi-gene hereditary cancer panel'],
    linked_drugs: ['Lynparza (olaparib)'],
    regulatory_status: 'LDT',
    genes_in_panel: 80,
    turnaround_days: 14,
    test_price_estimate: 2500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 100000,
    estimated_revenue_m: 180,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'Broad hereditary cancer panel',
      'Strong genetic counseling network',
      'Reclassification program (VUS reduction)',
      'Extensive variant database',
    ],
    weaknesses: ['LDT only', 'Smaller brand than Myriad', 'Konica Minolta ownership uncertainty', 'No CDx approvals'],
    source: 'GenomeWeb; Konica Minolta reports 2024',
    last_updated: '2025-01',
  },
];

// =============================================================================
// ONCOLOGY PROGNOSTIC / TREATMENT SELECTION
// =============================================================================

const PROGNOSTIC: CDxCompetitor[] = [
  {
    company: 'Exact Sciences',
    test_name: 'Oncotype DX Breast',
    platform: 'PCR',
    biomarkers_covered: ['21-gene expression (RS score)', 'ESR1', 'PGR', 'ERBB2', 'Ki67'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 21,
    turnaround_days: 10,
    test_price_estimate: 4175,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 700,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Standard of care for HR+/HER2- breast cancer',
      'TAILORx + RxPONDER RCT data',
      'CMS coverage',
      'NCCN Category 1',
      'Avoids unnecessary chemo',
    ],
    weaknesses: [
      'Breast cancer only',
      'RT-PCR platform (older technology)',
      'Competition from Prosigna/MammaPrint',
      'Patent expiration approaching',
    ],
    source: 'Exact Sciences 10-K 2024; TAILORx, RxPONDER trials',
    last_updated: '2025-01',
  },
  {
    company: 'Veracyte',
    test_name: 'Decipher Prostate',
    platform: 'microarray',
    biomarkers_covered: ['22-gene genomic classifier (GC score)'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 22,
    turnaround_days: 10,
    test_price_estimate: 3800,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 100000,
    estimated_revenue_m: 300,
    differentiation_score: 8,
    evidence_strength: 9,
    strengths: [
      'Leading prostate genomic test',
      'NCCN Category 1',
      'CMS coverage (both biopsy and RP)',
      'Validated in 20+ clinical studies',
    ],
    weaknesses: ['Prostate only', 'Competition from Prolaris/OncotypeDX Prostate', 'Tissue required', 'LDT status'],
    source: 'Veracyte 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Veracyte',
    test_name: 'Afirma Genomic Sequencing Classifier',
    platform: 'NGS',
    biomarkers_covered: ['Thyroid gene expression classifier', 'BRAF', 'RAS', 'RET', 'genomic alterations'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 593,
    turnaround_days: 5,
    test_price_estimate: 3200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 80000,
    estimated_revenue_m: 200,
    differentiation_score: 9,
    evidence_strength: 8,
    strengths: ['Gold standard thyroid FNA classifier', 'Avoids unnecessary surgery', 'CMS coverage', 'High NPV (96%)'],
    weaknesses: ['Thyroid only', 'LDT', 'Niche market', 'Competition from ThyroSeq'],
    source: 'Veracyte 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Veracyte',
    test_name: 'Percepta Nasal Swab',
    platform: 'NGS',
    biomarkers_covered: ['Nasal gene expression classifier (lung cancer risk)'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 30,
    turnaround_days: 5,
    test_price_estimate: 2800,
    sample_type: ['nasal swab'],
    estimated_annual_test_volume: 20000,
    estimated_revenue_m: 45,
    differentiation_score: 8,
    evidence_strength: 7,
    strengths: [
      'Non-invasive nasal swab',
      'Rules out lung cancer in indeterminate nodules',
      'Novel collection method',
      'Growing adoption',
    ],
    weaknesses: ['Early commercial stage', 'Limited evidence base', 'Payer coverage building', 'Niche application'],
    source: 'Veracyte 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Agendia',
    test_name: 'MammaPrint',
    platform: 'microarray',
    biomarkers_covered: ['70-gene expression (breast cancer prognosis)'],
    linked_drugs: [],
    regulatory_status: 'cleared',
    genes_in_panel: 70,
    turnaround_days: 10,
    test_price_estimate: 4200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 50000,
    estimated_revenue_m: 170,
    differentiation_score: 7,
    evidence_strength: 9,
    strengths: ['MINDACT RCT data', 'FDA cleared (510k)', 'EU widely used', 'Combined with BluePrint for subtyping'],
    weaknesses: [
      'Second to Oncotype DX in US',
      'Higher tissue requirement',
      'Less US oncologist familiarity',
      'Declining US market share',
    ],
    source: 'FDA 510(k); Agendia press releases; MINDACT trial',
    last_updated: '2025-01',
  },
  {
    company: 'Biotheranostics',
    test_name: 'CancerTYPE ID',
    platform: 'PCR',
    biomarkers_covered: ['92-gene expression (cancer of unknown primary)'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 92,
    turnaround_days: 5,
    test_price_estimate: 3500,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 15000,
    estimated_revenue_m: 40,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'CUP identification from 50 tumor types',
      'CMS coverage',
      'Fast turnaround',
      'Clinical utility in guiding treatment',
    ],
    weaknesses: ['Niche market (CUP)', 'Small volume', 'LDT', 'Competition from comprehensive NGS panels'],
    source: 'Biotheranostics/Hologic; GenomeWeb',
    last_updated: '2025-01',
  },
];

// =============================================================================
// EMERGING / NEXT-GEN CDx
// =============================================================================

const EMERGING: CDxCompetitor[] = [
  {
    company: 'C2i Genomics',
    test_name: 'C2i MRD (whole-genome)',
    platform: 'NGS',
    biomarkers_covered: ['ctDNA (whole-genome MRD)', 'genome-wide SNVs'],
    linked_drugs: [],
    regulatory_status: 'development',
    genes_in_panel: 20000,
    turnaround_days: 14,
    test_price_estimate: 2500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 5000,
    estimated_revenue_m: 10,
    differentiation_score: 7,
    evidence_strength: 5,
    strengths: [
      'Tumor-naive approach (no prior tissue needed)',
      'Whole-genome depth',
      'Lower cost target',
      'Roche partnership',
    ],
    weaknesses: ['Pre-commercial scale', 'Limited validation data', 'Regulatory path unclear', 'Crowded MRD space'],
    source: 'C2i Genomics press releases; Roche partnership announcement',
    last_updated: '2025-01',
  },
  {
    company: 'Resolution Bioscience (Agilent)',
    test_name: 'Resolution ctDx Lung',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'MET', 'RET', 'HER2'],
    linked_drugs: [],
    regulatory_status: 'development',
    genes_in_panel: 21,
    turnaround_days: 7,
    test_price_estimate: 3000,
    sample_type: ['blood'],
    estimated_annual_test_volume: 10000,
    estimated_revenue_m: 25,
    differentiation_score: 6,
    evidence_strength: 5,
    strengths: ['Agilent backing', 'Hybrid capture liquid biopsy', 'Focused NSCLC panel', 'Low DNA input requirement'],
    weaknesses: ['Pre-PMA', 'Crowded liquid biopsy space', 'Narrow panel', 'Behind Guardant/F1 Liquid'],
    source: 'Agilent press releases; GenomeWeb',
    last_updated: '2025-01',
  },
  {
    company: 'Burning Rock Biotech',
    test_name: 'OncoScreen Plus',
    platform: 'NGS',
    biomarkers_covered: ['EGFR', 'ALK', 'ROS1', 'BRAF', 'KRAS', 'MET', 'RET', 'HER2', 'TMB', 'MSI'],
    linked_drugs: [],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 520,
    turnaround_days: 10,
    test_price_estimate: 3000,
    sample_type: ['tissue', 'blood'],
    estimated_annual_test_volume: 300000,
    estimated_revenue_m: 180,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: ['Largest CGP provider in China', 'NMPA approved', 'Dual tissue + liquid', 'Rapid China market growth'],
    weaknesses: [
      'China-focused (limited US/EU)',
      'Regulatory challenges outside China',
      'US FDA approval not planned',
      'Currency/geopolitical risk',
    ],
    source: 'Burning Rock 20-F 2024; NMPA database',
    last_updated: '2025-01',
  },
];

// =============================================================================
// PHARMACOGENOMICS (PGx)
// =============================================================================

const PHARMACOGENOMICS: CDxCompetitor[] = [
  {
    company: 'Mayo Collaborative Services',
    test_name: 'DPYD Genotyping Assay',
    platform: 'PCR',
    biomarkers_covered: ['DPYD (*2A, *13, D949V, HapB3)'],
    linked_drugs: ['5-Fluorouracil (5-FU)', 'Capecitabine (Xeloda)'],
    regulatory_status: 'LDT',
    genes_in_panel: 1,
    turnaround_days: 5,
    test_price_estimate: 350,
    sample_type: ['blood'],
    estimated_annual_test_volume: 120000,
    estimated_revenue_m: 35,
    differentiation_score: 7,
    evidence_strength: 8,
    strengths: [
      'Prevents fatal fluoropyrimidine toxicity',
      'CPIC guideline supported',
      'EMA mandated pre-treatment testing (EU)',
      'Growing US adoption post-2020 DPWG/CPIC updates',
    ],
    weaknesses: [
      'Not FDA-required in US (voluntary)',
      'Limited awareness among community oncologists',
      'Only detects 4 key variants (misses rare alleles)',
      'Reimbursement inconsistent across US payers',
    ],
    source: 'CPIC guideline for fluoropyrimidines 2024; EMA SmPC requirement; Mayo test catalog',
    last_updated: '2025-01',
  },
  {
    company: 'Roche',
    test_name: 'cobas UGT1A1 Assay',
    platform: 'PCR',
    biomarkers_covered: ['UGT1A1 (*28, *6)'],
    linked_drugs: ['Irinotecan (Camptosar)', 'Belinostat (Beleodaq)'],
    regulatory_status: 'cleared',
    genes_in_panel: 1,
    turnaround_days: 3,
    test_price_estimate: 300,
    sample_type: ['blood'],
    estimated_annual_test_volume: 80000,
    estimated_revenue_m: 20,
    differentiation_score: 6,
    evidence_strength: 8,
    strengths: [
      'FDA-cleared IVD',
      'Irinotecan label recommends UGT1A1 testing',
      'Prevents severe neutropenia and diarrhea',
      'Runs on widely installed cobas platform',
    ],
    weaknesses: [
      'Single gene only',
      'Dose adjustment guidance still evolving',
      'Many oncologists skip testing',
      'Low revenue per test',
    ],
    source: 'FDA 510(k) K061029; Irinotecan FDA label; Roche Diagnostics catalog',
    last_updated: '2025-01',
  },
  {
    company: 'ARUP Laboratories',
    test_name: 'TPMT/NUDT15 Genotyping Panel',
    platform: 'PCR',
    biomarkers_covered: ['TPMT (*2, *3A, *3B, *3C)', 'NUDT15 (*3, *4, *5)'],
    linked_drugs: ['Azathioprine (Imuran)', 'Mercaptopurine (6-MP)', 'Thioguanine'],
    regulatory_status: 'LDT',
    genes_in_panel: 2,
    turnaround_days: 5,
    test_price_estimate: 280,
    sample_type: ['blood'],
    estimated_annual_test_volume: 150000,
    estimated_revenue_m: 35,
    differentiation_score: 6,
    evidence_strength: 9,
    strengths: [
      'FDA label requires TPMT/NUDT15 testing before thiopurines',
      'Prevents life-threatening myelosuppression',
      'CPIC guideline with actionable dose tiers',
      'Critical in pediatric ALL treatment',
    ],
    weaknesses: [
      'Low ASP per test',
      'Generic drugs limit pharma investment in CDx',
      'NUDT15 coverage inconsistent across labs',
      'LDT — no FDA-cleared kit widely available',
    ],
    source: 'CPIC guideline for thiopurines 2024; FDA mercaptopurine label; ARUP test menu',
    last_updated: '2025-01',
  },
  {
    company: 'Quest Diagnostics',
    test_name: 'HLA-B*5701 Screening',
    platform: 'PCR',
    biomarkers_covered: ['HLA-B*5701'],
    linked_drugs: ['Abacavir (Ziagen)', 'Abacavir/Lamivudine (Epzicom)'],
    regulatory_status: 'LDT',
    genes_in_panel: 1,
    turnaround_days: 3,
    test_price_estimate: 150,
    sample_type: ['blood'],
    estimated_annual_test_volume: 250000,
    estimated_revenue_m: 30,
    differentiation_score: 7,
    evidence_strength: 10,
    strengths: [
      'FDA black box warning mandates testing before abacavir',
      'Highest clinical utility PGx test — prevents hypersensitivity',
      '100% testing rate in HIV clinics',
      'PREDICT-1 trial gold-standard evidence',
    ],
    weaknesses: [
      'Very low per-test price',
      'Commodity test offered by all major labs',
      'Limited growth — HIV treatment paradigm shifting',
      'No differentiation between labs',
    ],
    source: 'FDA abacavir label (black box); PREDICT-1 trial; CPIC HLA guideline',
    last_updated: '2025-01',
  },
  {
    company: 'Myriad Genetics',
    test_name: 'GeneSight CYP2D6 Panel',
    platform: 'PCR',
    biomarkers_covered: ['CYP2D6 (>30 alleles)', 'CYP2D6 copy number'],
    linked_drugs: ['Tamoxifen', 'Codeine', 'Tramadol', 'Ondansetron', 'Venlafaxine'],
    regulatory_status: 'LDT',
    genes_in_panel: 1,
    turnaround_days: 5,
    test_price_estimate: 330,
    sample_type: ['buccal swab'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 55,
    differentiation_score: 7,
    evidence_strength: 7,
    strengths: [
      'Critical for tamoxifen efficacy (breast cancer)',
      'FDA safety communication on codeine in children',
      'Part of GeneSight multi-gene panel',
      'CYP2D6 star allele translation well-validated',
    ],
    weaknesses: [
      'CYP2D6 genotyping technically complex (gene deletions/duplications)',
      'Tamoxifen CYP2D6 utility still debated by some KOLs',
      'Clinical utility for pain management contested',
      'Payer coverage variable',
    ],
    source: 'CPIC CYP2D6 guideline 2024; Myriad 10-K 2024; FDA codeine safety communication',
    last_updated: '2025-01',
  },
  {
    company: 'OneOme',
    test_name: 'RightMed CYP2C19 Panel',
    platform: 'PCR',
    biomarkers_covered: ['CYP2C19 (*2, *3, *4, *8, *17)'],
    linked_drugs: ['Clopidogrel (Plavix)', 'Prasugrel (Effient)', 'Voriconazole', 'Omeprazole', 'Escitalopram'],
    regulatory_status: 'LDT',
    genes_in_panel: 1,
    turnaround_days: 3,
    test_price_estimate: 250,
    sample_type: ['blood', 'buccal swab'],
    estimated_annual_test_volume: 180000,
    estimated_revenue_m: 40,
    differentiation_score: 7,
    evidence_strength: 9,
    strengths: [
      'FDA boxed warning on clopidogrel for CYP2C19 poor metabolizers',
      'TAILOR-PCI RCT data supports genotype-guided antiplatelet therapy',
      'Mayo Clinic co-development',
      'Broad clinical impact across cardiology and psychiatry',
    ],
    weaknesses: [
      'Competitive commodity PGx space',
      'Hospital-based testing growing (reducing send-out volume)',
      'Insurance coverage building but not universal',
      'OneOme smaller brand vs Myriad/Quest',
    ],
    source: 'CPIC CYP2C19 guideline 2024; TAILOR-PCI trial; FDA clopidogrel label (boxed warning)',
    last_updated: '2025-01',
  },
];

// =============================================================================
// NON-ONCOLOGY DIAGNOSTICS
// =============================================================================

const NON_ONCOLOGY: CDxCompetitor[] = [
  {
    company: 'Abbott',
    test_name: 'ARCHITECT STAT High Sensitive Troponin-I',
    platform: 'IHC',
    biomarkers_covered: ['High-sensitivity cardiac troponin I (hs-cTnI)'],
    linked_drugs: [],
    regulatory_status: 'cleared',
    turnaround_days: 0,
    test_price_estimate: 25,
    sample_type: ['blood'],
    estimated_annual_test_volume: 80000000,
    estimated_revenue_m: 1600,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Fastest hs-cTnI result (<18 minutes)',
      'FDA-cleared with sex-specific cutoffs',
      'Installed base of 50K+ ARCHITECT analyzers globally',
      'ESC 0/1h and 0/2h algorithm validated',
      'Massive test volume in emergency departments',
    ],
    weaknesses: [
      'Commodity test — intense price competition',
      'Platform lock-in dependent (ARCHITECT/Alinity)',
      'Point-of-care troponin alternatives emerging',
      'Roche hs-cTnT entrenched in many health systems',
    ],
    source: 'FDA 510(k); Abbott 10-K 2024; ESC 2023 ACS guidelines',
    last_updated: '2025-01',
  },
  {
    company: 'Roche Diagnostics',
    test_name: 'Elecsys NT-proBNP',
    platform: 'IHC',
    biomarkers_covered: ['NT-proBNP (heart failure biomarker)'],
    linked_drugs: ['Entresto (sacubitril/valsartan)'],
    regulatory_status: 'cleared',
    turnaround_days: 0,
    test_price_estimate: 35,
    sample_type: ['blood'],
    estimated_annual_test_volume: 60000000,
    estimated_revenue_m: 1700,
    differentiation_score: 8,
    evidence_strength: 10,
    strengths: [
      'Gold standard heart failure biomarker',
      'FDA-cleared diagnostic and monitoring',
      'Linked to Entresto prescribing guidelines',
      'cobas platform widely installed',
      'ACC/AHA guideline recommended',
    ],
    weaknesses: [
      'Commodity immunoassay pricing',
      'BNP vs NT-proBNP debate persists',
      'Point-of-care competitors eroding lab share',
      'Age/BMI/renal confounders affect interpretation',
    ],
    source: 'FDA 510(k); Roche 10-K 2024; ACC/AHA heart failure guidelines 2023',
    last_updated: '2025-01',
  },
  {
    company: 'Roche Diagnostics',
    test_name: 'cobas HPV Test',
    platform: 'PCR',
    biomarkers_covered: ['HPV 16', 'HPV 18', 'HPV high-risk pooled (12 genotypes)'],
    linked_drugs: [],
    regulatory_status: 'PMA_approved',
    turnaround_days: 1,
    test_price_estimate: 40,
    sample_type: ['cervical swab'],
    estimated_annual_test_volume: 25000000,
    estimated_revenue_m: 850,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'FDA-approved primary cervical cancer screening (first HPV test for this use)',
      'Highest test volume globally',
      'ATHENA trial evidence base',
      'ACS guideline: HPV primary screening preferred starting age 25',
      'Automated on cobas 6800/8800',
    ],
    weaknesses: [
      'Competitive with Hologic Aptima and BD Onclarity',
      'Declining Pap+HPV co-testing reducing dual-test revenue',
      'Self-collection HPV tests emerging as disruptors',
      'Screening interval extending to 5 years reduces per-patient volume',
    ],
    source: 'FDA PMA P100020; ATHENA trial; ACS cervical screening guideline 2024; Roche 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'bioMérieux',
    test_name: 'VIDAS B·R·A·H·M·S PCT (Procalcitonin)',
    platform: 'IHC',
    biomarkers_covered: ['Procalcitonin (PCT)', 'sepsis biomarker'],
    linked_drugs: [],
    regulatory_status: 'cleared',
    turnaround_days: 0,
    test_price_estimate: 30,
    sample_type: ['blood'],
    estimated_annual_test_volume: 40000000,
    estimated_revenue_m: 950,
    differentiation_score: 8,
    evidence_strength: 9,
    strengths: [
      'FDA-cleared for antibiotic stewardship guidance',
      'CMS reimbursement established',
      'Reduces unnecessary antibiotic use by 30-40%',
      'Surviving Sepsis Campaign guideline recommended',
      'Critical COVID-19 era adoption surge',
    ],
    weaknesses: [
      'Patent/licensing from Thermo Fisher (B·R·A·H·M·S)',
      'Multiple competitors now in PCT space (Roche, Abbott, Siemens)',
      'Interpretation requires clinical context',
      'Not specific — elevated in non-infectious inflammation',
    ],
    source: 'FDA 510(k); bioMérieux 2024 annual report; Surviving Sepsis Campaign 2021',
    last_updated: '2025-01',
  },
  {
    company: 'Natera',
    test_name: 'Panorama NIPT',
    platform: 'NGS',
    biomarkers_covered: [
      'cfDNA trisomy 21 (Down syndrome)',
      'trisomy 18',
      'trisomy 13',
      'sex chromosome aneuploidies',
      'microdeletions (22q11.2, 1p36, Angelman, Prader-Willi, Cri-du-chat)',
    ],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 0,
    turnaround_days: 7,
    test_price_estimate: 500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 1500000,
    estimated_revenue_m: 600,
    differentiation_score: 9,
    evidence_strength: 9,
    strengths: [
      'Market-leading NIPT (SNP-based, not counting-based)',
      'Lowest false positive rate for trisomy 21 among NIPTs',
      'Detects triploidy uniquely',
      'ACOG/SMFM recommends NIPT for all pregnancies (2023)',
      'Microdeletion screening differentiator',
    ],
    weaknesses: [
      'LDT — not FDA approved',
      'Microdeletion PPV low in average-risk pregnancies',
      'Ethical concerns around expanded screening',
      'Insurance coverage variable for average-risk population',
      'Competition from Illumina VeriSeq, Roche Harmony',
    ],
    source: 'Natera 10-K 2024; ACOG Practice Bulletin 226; SMART study',
    last_updated: '2025-01',
  },
  {
    company: 'C2N Diagnostics',
    test_name: 'PrecivityAD2 (p-tau217 + Aβ42/40)',
    platform: 'IHC',
    biomarkers_covered: ['p-tau217', 'Aβ42/40 ratio', 'Alzheimer disease blood biomarker'],
    linked_drugs: ['Leqembi (lecanemab)', 'Kisunla (donanemab)'],
    regulatory_status: 'LDT',
    genes_in_panel: 0,
    turnaround_days: 10,
    test_price_estimate: 1250,
    sample_type: ['blood'],
    estimated_annual_test_volume: 50000,
    estimated_revenue_m: 50,
    differentiation_score: 10,
    evidence_strength: 8,
    strengths: [
      'First commercial blood test for Alzheimer pathology',
      'p-tau217 has >95% accuracy vs amyloid PET',
      'Critical gatekeeper for anti-amyloid therapy eligibility (Leqembi, Kisunla)',
      'Eliminates need for PET or CSF in many patients',
      'Massive TAM as anti-amyloid drugs scale',
    ],
    weaknesses: [
      'LDT only — FDA submission anticipated 2025-2026',
      'Reimbursement not established (self-pay or insurer negotiation)',
      'Competition from Lumipulse, Elecsys, Fujirebio platforms',
      'Cutoff thresholds still being validated across diverse populations',
      'Lab capacity currently limited',
    ],
    source: 'C2N Diagnostics press releases; TRAILBLAZER-ALZ 2; Lancet Neurology 2024 p-tau217 validation',
    last_updated: '2025-01',
  },
];

// =============================================================================
// ADVANCED ONCOLOGY DIAGNOSTICS
// =============================================================================

const ADVANCED_ONCOLOGY: CDxCompetitor[] = [
  {
    company: 'Invivoscribe (Adaptive Biotechnologies)',
    test_name: 'clonoSEQ MRD',
    platform: 'NGS',
    biomarkers_covered: ['IgH VDJ', 'IgH DJ', 'IgK', 'TCRβ', 'TCRδ', 'TCRγ (MRD hematologic malignancies)'],
    linked_drugs: [],
    regulatory_status: 'cleared',
    genes_in_panel: 6,
    turnaround_days: 5,
    test_price_estimate: 3100,
    sample_type: ['blood', 'bone marrow'],
    estimated_annual_test_volume: 100000,
    estimated_revenue_m: 250,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Only FDA-cleared MRD test (all hematologic malignancies)',
      'Sensitivity to 10^-6 (1 in a million)',
      'CMS coverage for ALL, CLL, and multiple myeloma',
      'Used as endpoint in major clinical trials (MASTER, MAIA)',
      'NCCN guideline incorporated',
    ],
    weaknesses: [
      'Hematologic malignancies only — no solid tumor application',
      'Requires baseline sample for clonotype identification',
      'Adaptive Biotechnologies financial challenges',
      'Competition from flow cytometry MRD in some centers',
    ],
    source: 'FDA 510(k) K173362; CMS NCD; Adaptive Biotechnologies 10-K 2024',
    last_updated: '2025-01',
  },
  {
    company: 'Myriad Genetics',
    test_name: 'myChoice CDx HRD',
    platform: 'NGS',
    biomarkers_covered: [
      'HRD (homologous recombination deficiency)',
      'BRCA1',
      'BRCA2',
      'genomic instability score (GIS)',
      'LOH',
      'TAI',
      'LST',
    ],
    linked_drugs: ['Lynparza (olaparib)', 'Zejula (niraparib)'],
    regulatory_status: 'PMA_approved',
    genes_in_panel: 2,
    turnaround_days: 14,
    test_price_estimate: 4200,
    sample_type: ['tissue'],
    estimated_annual_test_volume: 160000,
    estimated_revenue_m: 530,
    differentiation_score: 9,
    evidence_strength: 10,
    strengths: [
      'Only FDA-approved HRD assay',
      'CDx for two PARP inhibitors (olaparib, niraparib)',
      'Composite GIS score (LOH + TAI + LST) uniquely validated',
      'Critical gatekeeper for ovarian and breast cancer PARP treatment',
      'NCCN Category 1 recommendation',
    ],
    weaknesses: [
      'Tissue-only — cannot run on liquid biopsy',
      '14-day turnaround delays treatment decisions',
      'GIS cutoff (≥42) debated in prostate and pancreatic cancers',
      'Competition from SOPHiA DDM and AmoyDx HRD assays',
      'HRD reversion detection not addressed',
    ],
    source: 'FDA PMA P190014; Myriad 10-K 2024; PAOLA-1 trial; PRIMA/ENGOT-OV26 trial',
    last_updated: '2025-01',
  },
  {
    company: 'Natera',
    test_name: 'Signatera Tumor-Informed ctDNA',
    platform: 'PCR',
    biomarkers_covered: ['ctDNA (personalized tumor-informed MRD)', '16 custom SNVs per patient'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 16,
    turnaround_days: 10,
    test_price_estimate: 3500,
    sample_type: ['blood'],
    estimated_annual_test_volume: 250000,
    estimated_revenue_m: 650,
    differentiation_score: 9,
    evidence_strength: 9,
    strengths: [
      'Market-leading tumor-informed ctDNA MRD test',
      'CMS coverage for CRC, breast cancer, bladder cancer, ICI monitoring',
      'Serial monitoring enables treatment response tracking',
      'CIRCULATE-Japan and IMvigor010 data',
      'NCCN guideline included for CRC MRD',
    ],
    weaknesses: [
      'Requires prior tumor tissue for custom panel design',
      'Initial turnaround longer than tumor-naive approaches',
      'Expensive across full monitoring lifecycle ($3,500 per draw)',
      'PCR-based sensitivity ceiling vs WGS approaches',
      'Reimbursement for serial monitoring still evolving',
    ],
    source: 'Natera 10-K 2024; CIRCULATE-Japan; IMvigor010; CMS LCD L39046',
    last_updated: '2025-01',
  },
  {
    company: 'GRAIL (Illumina)',
    test_name: 'Galleri Multi-Cancer Early Detection',
    platform: 'NGS',
    biomarkers_covered: ['cfDNA methylation patterns (50+ cancer types)', 'Cancer Signal Origin (CSO)'],
    linked_drugs: [],
    regulatory_status: 'LDT',
    genes_in_panel: 0,
    turnaround_days: 14,
    test_price_estimate: 949,
    sample_type: ['blood'],
    estimated_annual_test_volume: 200000,
    estimated_revenue_m: 160,
    differentiation_score: 10,
    evidence_strength: 7,
    strengths: [
      'First MCED test — detects 50+ cancer types from single blood draw',
      'Cancer Signal Origin localization (where in body)',
      'NHS-Galleri trial (140K participants) largest MCED RCT',
      'Addresses cancers with no screening (pancreas, ovarian, liver)',
      'Massive TAM: 100M+ adults aged 50+ in US alone',
    ],
    weaknesses: [
      'No FDA approval yet (PMA submission planned)',
      'Self-pay only ($949) — no insurance coverage',
      'Stage I sensitivity low (~17% across all cancers)',
      'Specificity 99.5% still yields false positives at scale',
      'Illumina GRAIL divestiture creates organizational uncertainty',
    ],
    source: 'GRAIL press releases 2024; PATHFINDER trial; NHS-Galleri interim results; GenomeWeb',
    last_updated: '2025-01',
  },
  {
    company: 'Guardant Health',
    test_name: 'Guardant Shield MCED',
    platform: 'liquid_biopsy',
    biomarkers_covered: ['cfDNA methylation + fragmentomics (multi-cancer screening)'],
    linked_drugs: [],
    regulatory_status: 'development',
    genes_in_panel: 0,
    turnaround_days: 14,
    test_price_estimate: 900,
    sample_type: ['blood'],
    estimated_annual_test_volume: 0,
    estimated_revenue_m: 0,
    differentiation_score: 8,
    evidence_strength: 5,
    strengths: [
      'Leverages Guardant liquid biopsy infrastructure',
      'ECLIPSE-like methodology extended to multi-cancer',
      'Strong commercial distribution network from Guardant360',
      'Fragmentomics + methylation dual-signal approach',
    ],
    weaknesses: [
      'Pre-market — no clinical data publicly available yet',
      'Behind GRAIL Galleri in development timeline',
      'Regulatory pathway for MCED still being defined by FDA',
      'TAM dependent on CMS coverage decision for MCED class',
    ],
    source: 'Guardant Health 10-K 2024; investor presentations; GenomeWeb',
    last_updated: '2025-01',
  },
];

// =============================================================================
// COMBINED DATABASE + LOOKUP FUNCTIONS
// =============================================================================

export const CDX_COMPETITOR_DATABASE: CDxCompetitor[] = [
  ...NGS_PANELS,
  ...LIQUID_BIOPSY,
  ...SCREENING,
  ...MRD_MONITORING,
  ...IHC_TESTS,
  ...PCR_TESTS,
  ...HEREDITARY,
  ...PROGNOSTIC,
  ...EMERGING,
  ...PHARMACOGENOMICS,
  ...NON_ONCOLOGY,
  ...ADVANCED_ONCOLOGY,
];

/**
 * Find CDx competitors that cover a specific biomarker.
 * Fuzzy matches biomarker names (case-insensitive, partial match).
 */
export function getCDxCompetitorsByBiomarker(biomarker: string): CDxCompetitor[] {
  const needle = biomarker.toLowerCase().trim();
  return CDX_COMPETITOR_DATABASE.filter((c) =>
    c.biomarkers_covered.some((b) => b.toLowerCase().includes(needle) || needle.includes(b.toLowerCase())),
  );
}

/**
 * Find CDx competitors by platform type.
 */
export function getCDxCompetitorsByPlatform(platform: CDxPlatform): CDxCompetitor[] {
  return CDX_COMPETITOR_DATABASE.filter((c) => c.platform === platform);
}

/**
 * Find CDx competitors linked to a specific drug.
 * Fuzzy matches drug names (case-insensitive, partial match).
 */
export function getCDxCompetitorsByLinkedDrug(drug: string): CDxCompetitor[] {
  const needle = drug.toLowerCase().trim();
  return CDX_COMPETITOR_DATABASE.filter((c) =>
    c.linked_drugs.some((d) => d.toLowerCase().includes(needle) || needle.includes(d.toLowerCase())),
  );
}

/**
 * Get all unique biomarkers covered across the database.
 */
export function getCoveredBiomarkers(): string[] {
  const biomarkers = new Set<string>();
  for (const c of CDX_COMPETITOR_DATABASE) {
    for (const b of c.biomarkers_covered) {
      biomarkers.add(b);
    }
  }
  return Array.from(biomarkers).sort();
}

/**
 * Find CDx competitors by company name.
 */
export function getCDxCompetitorsByCompany(company: string): CDxCompetitor[] {
  const needle = company.toLowerCase().trim();
  return CDX_COMPETITOR_DATABASE.filter((c) => c.company.toLowerCase().includes(needle));
}

/**
 * Find CDx competitors by regulatory status.
 */
export function getCDxCompetitorsByStatus(status: CDxCompetitor['regulatory_status']): CDxCompetitor[] {
  return CDX_COMPETITOR_DATABASE.filter((c) => c.regulatory_status === status);
}
